Clinical Trials Browser

Hematologic Diseases × Cyclophosphamide × Plasma cell × Clear all

Hematologic Diseases, Multiple Myeloma

NCT03246906 2025-06-04

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematologic Diseases, Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Phase 2 Completed

156 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hematologic Diseases, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

51 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Phase 2 Completed

176 enrolled 18 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00636909 2017-04-06

MINI HEME

Phase 2 Completed

25 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Blast Crisis, Hematologic Diseases, Hodgkin Disease, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Myeloid, Chronic-Phase

NCT00800839 2016-09-19

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Phase 2 Completed

56 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hematologic Diseases, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Clinical Trials

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Allo HSCT Using RIC for Hematological Diseases

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

MINI HEME

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide